

## **Exhibit 2**

### **Claims as Pending following Entry of Amendment**

15. (Amended)        A monoclonal antibody to human IL-12 which consists of a p35 subunit and a p40 subunit forming a p75 heterodimer, wherein said monoclonal antibody
- (a)       immunologically reacts with an epitope presented by the p75 heterodimer of human IL-12, but is not immunologically reactive with any epitope presented by said p40 subunit; and
  - (b)       neutralizes at least about 90% of the bioactivity of human IL-12, wherein the antibody neutralizes at least about 90% bioactivity of human IL-12 by inhibiting IL-12 stimulated PHA-activated human lymphoblast proliferation wherein the concentration of said antibody is 0.5  $\mu$ g/ml and the concentration of said human IL-12 is 0.25 ng/ml.
16. (Amended)        A monoclonal antibody to human IL-12 which consists of a p35 subunit and a p40 subunit forming a p75 heterodimer, wherein said monoclonal antibody
- (a)       immunologically reacts with an epitope presented by the p75 heterodimer of human IL-12, but is not immunologically reactive with any epitope presented by said p40 subunit; and
  - (b)       neutralizes at least about 90% of the bioactivity of human IL-12, wherein the antibody neutralizes at least about 90% bioactivity of human IL-12 by inhibiting IL-12 stimulated IFN- $\gamma$  production wherein the concentration of the antibody is 0.5  $\mu$ g/ml and the concentration of said human IL-12 is 0.25 ng/ml.
17. (Amended)        The antibody of claim 15, wherein the antibody cross reacts with rhesus monkey IL-12.

18. (Amended)      The antibody of claim 15, wherein the antibody is humanized.
19. (Amended)      The antibody of claim 15, wherein the antibody is produced by a hybridoma.
20. (Amended)      The antibody of claim 19, wherein the antibody has been humanized.
37. (New)      The antibody of claim 16, wherein the antibody cross reacts with rhesus monkey IL-12.
38. (New)      The antibody of claim 16, wherein the antibody is humanized.
39. (New)      The antibody of claim 16, wherein the antibody is produced by a hybridoma.
40. (New)      The antibody of claim 39, wherein the antibody has been humanized.